A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer - PubMed
a day ago
- #chemotherapy
- #ketogenic diet
- #pancreatic cancer
- A randomized phase II trial evaluated gemcitabine, nab-paclitaxel, and cisplatin with or without a medically supervised ketogenic diet (MSKD) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
- Patients were randomized 1:1 to MSKD or non-MSKD groups, with the MSKD group achieving nutritional ketosis in 15 out of 16 patients.
- The median progression-free survival (PFS) was 8.5 months in the MSKD group vs. 6.2 months in the non-MSKD group, with a hazard ratio of 0.53.
- Median overall survival (OS) was 13.7 months for MSKD vs. 10.2 months for non-MSKD, with a hazard ratio of 0.58.
- All MSKD-related adverse events were grade 1-2, with no significant differences in severe chemotherapy-related adverse events between groups.
- Quality of life (QOL) did not decline in the MSKD group, and there was significant enrichment of beneficial microbiome taxa.
- The study concluded that MSKD is feasible and shows trends toward improved PFS and OS without added toxicity or QOL detriment, though larger studies are needed for confirmation.